Currently, SM08502 is being evaluated in a Phase 1, open-label, multicenter, dose escalation study (NCT03355066) in 42 adult patients with advanced solid tumors for whom standard therapy is not available for their stage of diagnosis.
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor.
The ‘BiliScreen’ app uses a smartphone camera; by taking a picture of the user’s eyes it can calculate the color formation of the sclera and correlates it to the correct bilirubin level
Data on nutritional markers (body mass index [BMI], albumin, total cholesterol) were collected at baseline and then assessed at 16 weeks; change from baseline was compared between the two groups.
Ability Pharmaceuticals has announced that the Food and Drug Administration has granted orphan drug designation to ABTL0812, an investigational candidate for pancreatic cancer.
For patients with type 2 diabetes mellitus (T2DM), use of statins offsets insulin-related cancer risks, according to research published online in the Journal of Internal Medicine.
Scientists who discovered that pancreatic cancer is at least four separate diseases say their findings could lead to improved treatments for the disease.
A new international, multicenter study has found that incretin-based drugs, used to treat type 2 diabetes, are not associated with an increased risk of pancreatic cancer.
Metformin may inhibit the progression of pancreatic cancer by decreasing inflammation and fibrosis, a study published in PLOS One reported.
A new study adds to the evidence that low-dose aspirin, known to reduce the risk for heart disease, may also reduce the risk for pancreatic cancer. Pancreatic cancer has a 93 percent fatality rate, and the National Cancer Institute estimates there will be about 46,000 new cases and 40,000 deaths from the disease this year.
